Cerebrospinal fluid biomarkers for Parkinson's disease – a systematic review

Acta Neurologica Scandinavica

Volumn 135, Issue 1, 2017, Pages 34-56

  Andersen, A D ^a,b   Binzer, M ^a,b   Stenager, E ^a,b,c   Gramsbergen, J B ^b  

^a Sonderborg Hospital   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c Multiple Sclerosis Clinic of Southern Jutland   (Denmark)

Author keywords

Alpha synuclein; Amyloid beta; biomarker; cerebrospinal fluid; metabolomics; neurofilament light chain; Parkinson's disease; Tau protein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PROTEIN; GROWTH FACTOR; NEUROFILAMENT PROTEIN; TAU PROTEIN; BIOLOGICAL MARKER;

CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE DURATION; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; HUMAN; LOCUS CERULEUS; LONGITUDINAL STUDY; MEDLINE; METABOLOMICS; NERVOUS SYSTEM INFLAMMATION; NORADRENERGIC NERVE CELL; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; RAPHE NUCLEUS; REVIEW; SEROTONINERGIC NERVE CELL; SUBSTANTIA NIGRA; SYSTEMATIC REVIEW; TRYPTOPHAN METABOLISM; META ANALYSIS;

ALPHA-SYNUCLEIN; BIOMARKERS; HUMANS; PARKINSON DISEASE; TAU PROTEINS;

EID: 84961276030     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12590     Document Type: Review

References (100)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525–35.
2. Rodriguez-Oroz MC, Jahanshahi M, Krack P et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009;8:1128–39.
3. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008;9:665–77.
4. Mollenhauer B, Zhang J. Biochemical premotor biomarkers for Parkinson's disease. Mov Disord 2012;27:644–50.
5. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol 2014;27:434–41.
6. Adler CH, Beach TG, Hentz JG et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014;83:406–12.
7. Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci 2014;8:369.
8. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211.
9. Goldstein DS, Holmes C, Sharabi Y. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain 2012;135:1900–13.
10. Goldstein DS, Holmes C, Bentho O et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008;14:600–7.
11. Lewitt P, Schultz L, Auinger P, Lu M, Parkinson Study Group DI. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain Res 2011;1408:88–97.
12. Lewitt PA, Li J, Lu M et al. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov Disord 2013;28:1653–60.
13. Abdo WF, Bloem BR, van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007;28:742–7.
14. Jenner P. Oxidative stress and Parkinson's disease. Handb Clin Neurol 2007;83:507–20.
15. Saito Y. Oxidized DJ-1 as a possible biomarker of Parkinson's disease. J Clin Biochem Nutr 2014;54:138–44.
16. Salvesen L, Bech S, Lokkegaard A et al. The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes. Parkinsonism Relat Disord 2012;18:899–901.
17. Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713–26.
18. Waragai M, Wei J, Fujita M et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006;345:967–72.
19. Herbert MK, Eeftens JM, Aerts MB et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord 2014;20:112–5.
20. Maarouf CL, Beach TG, Adler CH et al. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res 2012;34:669–76.
21. Forte G, Bocca B, Senofonte O et al. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J Neural Transm 2004;111:1031–40.
22. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 2008;33:1717–23.
23. Abe T, Isobe C, Murata T, Sato C, Tohgi H. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett 2003;336:105–8.
24. Kikuchi A, Takeda A, Onodera H et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 2002;9:244–8.
25. Garcia-Moreno JM, Martin De Pablos A, Garcia-Sanchez MI et al. May serum levels of advanced oxidized protein products serve as a prognostic marker of disease duration in patients with idiopathic Parkinson's disease? Antioxid Redox Signal 2013;18:1296–302.
26. Fernandez E, Garcia-Moreno JM, Martin DE, Pablos A, Chacon J. May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum alpha-synuclein serve for diagnosis of sporadic Parkinson's disease? Antioxid Redox Signal 2013;19:912–8.
27. Yu SY, Zuo LJ, Wang F et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol 2014;14:113.
28. Ascherio A, Lewitt PA, Xu K et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460–8.
29. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S210–2.
30. Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008;129:526–9.
31. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20.
32. Constantinescu R, Andreasson U, Li S et al. Proteomic profiling of cerebrospinal fluid in Parkinsonian disorders. Parkinsonism Relat Disord 2010;16:545–9.
33. Silajdzic E, Constantinescu R, Holmberg B, Bjorkqvist M, Hansson O. Flt3 ligand does not differentiate between Parkinsonian disorders. Mov Disord 2014;29:1319–22.
34. Shi M, Bradner J, Hancock AM et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570–80.
35. Pisani V, Stefani A, Pierantozzi M et al. Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J Neuroinflammation 2012;9:188.
36. Foltynie T, Cheeran B, Williams-Gray CH et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:141–4.
37. Sjogren M, Minthon L, Davidsson P et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000;107:563–79.
38. Dickson DW, Braak H, Duda JE et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150–7.
39. Foulds P, Mann DM, Allsop D. Phosphorylated alpha-synuclein as a potential biomarker for Parkinson's disease and related disorders. Expert Rev Mol Diagn 2012;12:115–7.
40. George S, Rey NL, Reichenbach N, Steiner JA, Brundin P. alpha-Synuclein: the long distance runner. Brain Pathol 2013;23:350–7.
41. Dunning CJ, George S, Brundin P. What's to like about the prion-like hypothesis for the spreading of aggregated alpha-synuclein in Parkinson disease? Prion 2013;7:92–7.
42. Pan-Montojo F, Schwarz M, Winkler C et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012;2:898.
43. Nielsen HM, Hall S, Surova Y et al. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. J Alzheimers Dis 2014;40:343–50.
44. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF alpha-synuclein does not differentiate between Parkinsonian disorders. Neurobiol Aging 2012;33:430 e1–3.
45. Tokuda T, Qureshi MM, Ardah MT et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75:1766–72.
46. Trupp M, Jonsson P, Ohrfelt A et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. J Parkinsons Dis 2014;4:549–60.
47. Foulds PG, Yokota O, Thurston A et al. Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis 2012;45:188–95.
48. Hall S, Ohrfelt A, Constantinescu R et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch Neurol 2012;69:1445–52.
49. van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WD. Reduced alpha-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 2014;21:388–94.
50. Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A. CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 2014;20:382–7.
51. Wennstrom M, Surova Y, Hall S et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 2013;8:e53250.
52. Heegaard NH, Tanassi JT, Bech S et al. Cerebrospinal fluid α-synuclein in the differential diagnosis of parkinsonian syndromes. Future Neurol 2014;9:525–32.
53. Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 2005;191(Suppl 1):S17–27.
54. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377:1019–31.
55. Parnetti L, Castrioto A, Chiasserini D et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013;9:131–40.
56. Parnetti L, Tiraboschi P, Lanari A et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64:850–5.
57. Sussmuth SD, Uttner I, Landwehrmeyer B et al. Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. Mov Disord 2010;25:1284–8.
58. Alves G, Bronnick K, Aarsland D et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81:1080–6.
59. Prikrylova Vranova H, Mares J, Nevrly M et al. CSF markers of neurodegeneration in Parkinson's disease. J Neural Transm 2010;117:1177–81.
60. Compta Y, Ibarretxe-Bilbao N, Pereira JB et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012;18:941–7.
61. Montine TJ, Shi M, Quinn JF et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682–5.
62. Nutu M, Bourgeois P, Zetterberg H et al. Abeta1-15/16 as a potential diagnostic marker in neurodegenerative diseases. Neuromolecular Med 2013;15:169–79.
63. Steinacker P, Fang L, Kuhle J et al. Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. PLoS One 2011;6:e23600.
64. Nutu M, Zetterberg H, Londos E et al. Evaluation of the cerebrospinal fluid amyloid-beta1-42/amyloid-beta1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders. Dement Geriatr Cogn Disord 2013;36:99–110.
65. Fleming CE, Nunes AF, Sousa MM. Transthyretin: more than meets the eye. Prog Neurobiol 2009;89:266–76.
66. Olsson B, Constantinescu R, Holmberg B, Andreasen N, Blennow K, Zetterberg H. The glial marker YKL-40 is decreased in synucleinopathies. Mov Disord 2013;28:1882–5.
67. Bech S, Hjermind LE, Salvesen L et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord 2012;18:69–72.
68. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230–40.
69. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183–98.
70. Brettschneider J, Petzold A, Sussmuth SD et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord 2006;21:2224–7.
71. Troster AI. Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for “mild cognitive impairment” and biomarkers. Neuropsychol Rev 2008;18:103–19.
72. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17:61–4.
73. Zhang J, Mattison HA, Liu C et al. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 2013;126:671–82.
74. Liu C, Cholerton B, Shi M et al. CSF tau and tau/Abeta42 predict cognitive decline in Parkinson's disease. Parkinsonism Relat Disord 2015;21:271–6.
75. Siderowf A, Xie SX, Hurtig H et al. CSF amyloid beta 1–42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055–61.
76. Compta Y, Pereira JB, Rios J et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013;19:717–24.
77. Alves G, Lange J, Blennow K et al. CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 2014;82:1784–90.
78. Salvesen L, Tanassi JT, Bech S et al. The influence of preanalytical conditions on the DJ-1 concentration in human cerebrospinal fluid. Biomark Med 2014;8:387–94.
79. Simonsen AH, Bahl JM, Danborg PB et al. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J Neurosci Methods 2013;215:234–40.
80. Teunissen CE, Petzold A, Bennett JL et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009;73:1914–22.
81. Lunardi G, Galati S, Tropepi D et al. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2009;15:383–9.
82. Ohlin KE, Francardo V, Lindgren HS et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 2011;134:2339–57.
83. Pisani V, Moschella V, Bari M et al. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Mov Disord 2010;25:920–4.
84. Isobe C, Murata T, Sato C, Terayama Y. Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease. J Clin Neurosci 2007;14:340–3.
85. Oeckl P, Steinacker P, von Arnim CA et al. Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration. J Proteome Res 2014;13:4518–25.
86. Shi M, Liu C, Cook TJ et al. Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol 2014;128:639–50.
87. Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2006;250:120–3.
88. Jesse S, Lehnert S, Jahn O et al. Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia. PLoS One 2012;7:e48783.
89. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.
90. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745–52.
91. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–9.
92. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9:417–23.
93. Koller WC. How accurately can Parkinson's disease be diagnosed? Neurology 1992;42:6–16; discussion 57-60.
94. Koller WC, Montgomery EB. Issues in the early diagnosis of Parkinson's disease. Neurology 1997;49:S10–25.
95. Daniel SE, Lees AJ. Parkinson's disease society brain bank, London: overview and research. J Neural Transm Suppl 1993;39:165–72.
96. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(Suppl):S125–7.
97. Brun A, Gustafson L, Wallin A. Swedish consensus on dementia diseases. Copenhagen: Munksgaard, 1994: 31 s.
98. Shoulson I. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group. Acta Neurol Scand Suppl 1989;126:171–5.
99. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989;15:27–44.
100. Jimenez-Jimenez FJ, Molina JA, Vargas C et al. Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. J Neural Transm (Vienna) 2000;107:445–9.